Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer

A 75-year-old man with stage IV lung adenocarcinoma was treated with osimertinib due to disease progression despite having been administered erlotinib. Both an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790M mutation on exon 20 were detected in a specimen from a recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Yoshiya, Kawaguchi, Tomoya, Yamamoto, Norio, Sawa, Kenji, Yoshimoto, Naoki, Suzumura, Tomohiro, Watanabe, Tetsuya, Mitsuoka, Shigeki, Asai, Kazuhisa, Kimura, Tatsuo, Yoshimura, Naruo, Kuwae, Yuko, Hirata, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635308/
https://www.ncbi.nlm.nih.gov/pubmed/28794368
http://dx.doi.org/10.2169/internalmedicine.8467-16
_version_ 1783270260125728768
author Matsumoto, Yoshiya
Kawaguchi, Tomoya
Yamamoto, Norio
Sawa, Kenji
Yoshimoto, Naoki
Suzumura, Tomohiro
Watanabe, Tetsuya
Mitsuoka, Shigeki
Asai, Kazuhisa
Kimura, Tatsuo
Yoshimura, Naruo
Kuwae, Yuko
Hirata, Kazuto
author_facet Matsumoto, Yoshiya
Kawaguchi, Tomoya
Yamamoto, Norio
Sawa, Kenji
Yoshimoto, Naoki
Suzumura, Tomohiro
Watanabe, Tetsuya
Mitsuoka, Shigeki
Asai, Kazuhisa
Kimura, Tatsuo
Yoshimura, Naruo
Kuwae, Yuko
Hirata, Kazuto
author_sort Matsumoto, Yoshiya
collection PubMed
description A 75-year-old man with stage IV lung adenocarcinoma was treated with osimertinib due to disease progression despite having been administered erlotinib. Both an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790M mutation on exon 20 were detected in a specimen from a recurrent primary tumor. Five weeks after osimertinib initiation, he developed general fatigue and dyspnea. Chest computed tomography scan revealed diffuse ground glass opacities and consolidation on both lungs. An analysis of the bronchoalveolar lavage fluid revealed marked lymphocytosis, and a transbronchial lung biopsy specimen showed a thickened interstitium with fibrosis and prominent lymphocytic infiltration. We diagnosed the patient to have interstitial lung disease induced by osimertinib.
format Online
Article
Text
id pubmed-5635308
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-56353082017-10-12 Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer Matsumoto, Yoshiya Kawaguchi, Tomoya Yamamoto, Norio Sawa, Kenji Yoshimoto, Naoki Suzumura, Tomohiro Watanabe, Tetsuya Mitsuoka, Shigeki Asai, Kazuhisa Kimura, Tatsuo Yoshimura, Naruo Kuwae, Yuko Hirata, Kazuto Intern Med Case Report A 75-year-old man with stage IV lung adenocarcinoma was treated with osimertinib due to disease progression despite having been administered erlotinib. Both an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790M mutation on exon 20 were detected in a specimen from a recurrent primary tumor. Five weeks after osimertinib initiation, he developed general fatigue and dyspnea. Chest computed tomography scan revealed diffuse ground glass opacities and consolidation on both lungs. An analysis of the bronchoalveolar lavage fluid revealed marked lymphocytosis, and a transbronchial lung biopsy specimen showed a thickened interstitium with fibrosis and prominent lymphocytic infiltration. We diagnosed the patient to have interstitial lung disease induced by osimertinib. The Japanese Society of Internal Medicine 2017-08-10 2017-09-01 /pmc/articles/PMC5635308/ /pubmed/28794368 http://dx.doi.org/10.2169/internalmedicine.8467-16 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Matsumoto, Yoshiya
Kawaguchi, Tomoya
Yamamoto, Norio
Sawa, Kenji
Yoshimoto, Naoki
Suzumura, Tomohiro
Watanabe, Tetsuya
Mitsuoka, Shigeki
Asai, Kazuhisa
Kimura, Tatsuo
Yoshimura, Naruo
Kuwae, Yuko
Hirata, Kazuto
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer
title Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer
title_full Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer
title_fullStr Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer
title_full_unstemmed Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer
title_short Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer
title_sort interstitial lung disease induced by osimertinib for epidermal growth factor receptor (egfr) t790m-positive non-small cell lung cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635308/
https://www.ncbi.nlm.nih.gov/pubmed/28794368
http://dx.doi.org/10.2169/internalmedicine.8467-16
work_keys_str_mv AT matsumotoyoshiya interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT kawaguchitomoya interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT yamamotonorio interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT sawakenji interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT yoshimotonaoki interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT suzumuratomohiro interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT watanabetetsuya interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT mitsuokashigeki interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT asaikazuhisa interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT kimuratatsuo interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT yoshimuranaruo interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT kuwaeyuko interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer
AT hiratakazuto interstitiallungdiseaseinducedbyosimertinibforepidermalgrowthfactorreceptoregfrt790mpositivenonsmallcelllungcancer

Ejemplares similares